Health and Healthcare

Biopharma Firm Crushed by Merck Deal Cancellation (CRME, MRK)

Canadian-based drug company Cardiome Pharma Corp. (NASDAQ: CRME) announced this morning that Merck & Co. Inc. (NYSE: MRK) has cancelled further development of an oral version of a Cardiome drug being reviewed as a maintenance treatment for long-term prevention of atrial fibrillation recurrence. Merck will continue distribution of the intravenous version of the product, which has been approved for use in 37 countries according to the Cardiome press release.

Cardiome said it plans to adopt a more austere budget for 2012:

… Cardiome will reduce its annual operating cash burn going forward to a target of approximately $11M before interest expense, roughly half of the current cash burn. The company ended 2011 with over $53M of cash and cash equivalents and received an additional $25M from the available line of credit from Merck in January 2012. Cardiome expects to release its 2011 year-end financial results on March 28th, 2012 which will allow time to make the necessary changes to its annual filings following this news.

Cardiome’s shares are down more than -53% at $0.91 after posting a new 52-week low this morning of $0.86. The 52-week high is $5.86.

Take Charge of Your Retirement In Just A Few Minutes (Sponsor)

Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance—and SmartAsset’s simple quiz makes it easier than ever for you to connect with a vetted financial advisor.

Here’s how it works:

  1. Answer a Few Simple Questions. Tell us a bit about your goals and preferences—it only takes a few minutes!
  2. Get Matched with Vetted Advisors Our smart tool matches you with up to three pre-screened, vetted advisors who serve your area and are held to a fiduciary standard to act in your best interests. Click here to begin
  3. Choose Your  Fit Review their profiles, schedule an introductory call (or meet in person), and select the advisor who feel is right for you.

Why wait? Start building the retirement you’ve always dreamed of. Click here to get started today!

 

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.

AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.